FGFR2 Inhibitor

FGFR2 Inhibitors (77):

Cat. No.	Product Name	Effect	Purity

HY-15813

FIIN-1	Inhibitor	99.11%
FIIN-1 is a potent, irreversible, selective FGFR inhibitor. FIIN-1 binds to FGFR1/2/3/4 and Flt1/4 with K_ds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC₅₀s of FIIN-1 are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively.

HY-18603

FIIN-3	Inhibitor	99.66%
FIIN-3 is an irreversible inhibitor of FGFR with an IC₅₀ of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

HY-159642

TYRA-300	Inhibitor	99.90%
TYRA-300 is an orally active, selective inhibitor for FGFR3 with an IC₅₀ of 11 nM in Ba/F3. TYRA-300 exhibits antitumor efficacy against urothelial cancers and solid tumors.

HY-147250A

Lirafugratinib hydrochloride	Inhibitor	98.96%
Lirafugratinib (RLY-4008) hydrochloride is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC₅₀ of 3 nM. Lirafugratinib hydrochloride covalently binds to Cys491. Lirafugratinib hydrochloride targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs.

HY-10987

ENMD-2076 Tartrate	Inhibitor	99.42%
ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC₅₀s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.

HY-10185

TG 100572 Hydrochloride	Inhibitor	98.96%
TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-131908

CPL304110	Inhibitor	99.85%
CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3), with IC₅₀ values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectively.

HY-131704

FGFR4-IN-5	Inhibitor	98.03%
FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC₅₀ of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research.

HY-145230

FGFR2-IN-1	Inhibitor	99.78%
FGFR2-IN-1 is a selective FGFR2 inhibitor with an IC₅₀ of 140 nM.

HY-12965

S49076	Inhibitor	99.44%
S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC₅₀ values below 20 nM.

HY-162865

FGFR2-IN-3	Inhibitor	98.28%
FGFR2-IN-3 is an inhibitor of fibroblast growth factor receptor 2 (FGFR2). FGFR2-IN-3 has good binding properties, forming key interactions and inducing conformational changes in FGFR2. FGFR2-IN-3 can be used for research on tumors.

HY-10184

TG 100572	Inhibitor
TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-101466A

E7090 succinate	Inhibitor	99.17%
E7090 succinate is an orally available, selective and potent inhibitor of FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC₅₀ values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively.

HY-117595

PHM16	Inhibitor
PHM16 is an ATP competitive inhibitor of FAK and FGFR2 (IC₅₀: 0.4 μM and 0.37 μM, respectively), with direct potent anti-angiogenic activity.

HY-101544

ARQ 069	Inhibitor
ARQ 069, an analog of ARQ 523, inhibits FGFR in an enantiospecific manner. ARQ 069 targets the unphosphorylated, inactive forms of FGFR1/FGFR2 kinases (IC₅₀s of 0.84 μM and 1.23 μM, respectively). ARQ 069 inhibits FGFR1/FGFR2 autophosphorylation (IC₅₀s of 2.8 and 1.9 μM, respectively) through a mechanism in a non-ATP competitive dependent manner.

HY-142921

FGFR-IN-2	Inhibitor
FGFR-IN-2 (compound 1) is a potent FGFR inhibitor with IC₅₀s of 7.3 nM, 4.3 nM, 7.6 nM, 11 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FGFR-IN-2 has the potential for cancer research.

HY-152104

FGFR-IN-9	Inhibitor
FGFR-IN-9 (Compound 19) is a potent, reversible and orally active FGFR inhibitor with an IC₅₀ of 17.1, 29.6, 30.7, 46.7 and 64.3 nM against FGFR4^WT, FGFR3, FGFR4^V550L, FGFR2 and FGFR1, respectively.

HY-150652

FGFR-IN-8	Inhibitor
FGFR-IN-8 (Compound 17a) is a highly potent and orally active panFGFR inhibitor against wild-type and mutant FGFRs. FGFR-IN-8 shows inhibition with IC₅₀ values of <0.5, 189.1, <0.5, 22.6, <0.5 and 7.30 nM against FGFR1, V564F-FGFR2, N549H-FGFR2, V555M-FGFR3, FGFR3 and FGFR4, respectively. GFR-IN-8 induces cancer cell apoptosis and shows anticancer activities.

HY-122704

Surfen	Inhibitor
Surfen is a potent heparan sulfate antagonist. Surfen inhibits FGF2 binding and signal transduction. Surfen binds to glycosaminoglycans and reduces tau hyperphosphorylation. Surfen inhibits the activity of recombinant uronyl 2-O-sulfotransferase with an IC₅₀ of approximately 2 μM. Surfen inhibits HSV-1 viral infection. Surfen inhibits neural differentiation, delays remyelination, and alleviates EAE.

HY-148597

FGFR-IN-10	Inhibitor
FGFR-IN-10 is an orally active inhibitor of FGFR and Cytochrome P450 (CYPs). FGFR-IN-10 inhibits wide type and V564F mutant FGFR2 with IC₅₀s of 104.1 nM and 43.6 nM, respectively. FGFR-IN-10 also inhibits CYPs with IC₅₀s of 3.33 μM (CYP2C9), 18.75 μM (CYP2C19), 4.34 μM (CYP2CD6), and 0.69 μM (CYP3A4), respectively.

Name
Email *

	Sorry, but the email address you supplied was invalid.